ChemicalBook > Product Catalog >API >Drugs Influencing Immune Function >Immunosuppressive drugs >GUSPERIMUS

GUSPERIMUS

GUSPERIMUS Suppliers list
Company Name: Dideu Industries Group Limited
Tel: +86-29-89586680 +86-15129568250
Email: 1026@dideu.com
Products Intro: Product Name:GUSPERIMUS
CAS:104317-84-2
Purity:99.9% Package:1g;1.1USD Remarks:FDA GMP CEP Approved Manufacturer
Company Name: Leancare Ltd.  
Tel: +33 962096793
Email: enquiry@leancare.co.uk
Products Intro:
Company Name: Lanospharma Laboratories Co.,Ltd  
Tel: 13440048448
Email: sales@lanospharma.com
Products Intro:
Company Name: CARBONE SCIENTIFIC CO.,LTD  
Tel: +44(0)870 486 8629
Email: sales@carbonesci.com
Products Intro:
Company Name: Waterstone Technology, LLC  
Tel: 317 644 0862
Email: sales@waterstonetech.com
Products Intro:

GUSPERIMUS manufacturers

  • GUSPERIMUS USP/EP/BP
  • GUSPERIMUS USP/EP/BP pictures
  • $1.10 / 1g
  • 2021-08-18
  • CAS:104317-84-2
  • Min. Order: 1g
  • Purity: 99.9%
  • Supply Ability: 100 Tons min
GUSPERIMUS Basic information
Product Name:GUSPERIMUS
Synonyms:BMS-181 173;Deoxyspergualin;NKT-01;NSC-356894:Spanidin;GUSPERIMUS;(±)-15-Deoxyspergualin;(±)-7-[(AminoiminomethyI)arnjno]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide;GUSPERIMUS USP/EP/BP
CAS:104317-84-2
MF:C17H37N7O3
MW:387.52
EINECS:
Product Categories:
Mol File:104317-84-2.mol
GUSPERIMUS Structure
GUSPERIMUS Chemical Properties
Safety Information
MSDS Information
GUSPERIMUS Usage And Synthesis
DescriptionGusperimus, a synthetic derivative of the antitumor antibiotic spergualin originally isolated from Bacillus laterosporus, was introduced in Japan as a treatment for accelerated and acute rejection reactions after kidney transplants. It possesses strong immunosuppressive activity including suppression of autoimmune disease, prolongation of survival of transplant allografts, induction of transplant tolerance, reversal of allograft rejection, inhibition of antibody responses, and suppression of delayed-type hypersensitivity. Although its activity is comparable to other agents as monotherapy, gusperimus in combination therapy (such as with cyclosporine A) has been reported to exhibit exceptional activity for prevention of transplant rejection and to induce long term tolerance. The mechanism of action appears to be due to inhibition of differentiation and proliferation of effector cells, including cytotoxic T cells and antibody producing B cells. Gusperimus is also in clinical trials for the treatment of graft rejection, multiple sclerosis, systemic lupus, diabetes mellitus, rheumatoid arthritis, nephrosis, and as an anticancer agent.
OriginatorNippon Kayaku (Japan)
DefinitionChEBI: Gusperimus is a N-acyl-amino acid.
Brand nameSpanidin
Tag:GUSPERIMUS(104317-84-2) Related Product Information
Gusperimus Hydrochloride GUSPERIMUS 3HCL Spergualin GUSPERIMUS